STOCK TITAN
  1. Home
  2. Sec-filings
  3. MCRB
  4. [8-K] Seres Therapeutics, Inc. Reports Material Event

[8-K] Seres Therapeutics, Inc. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Seres Therapeutics, Inc. reported a governance change with the resignation of board member Hans-Juergen Woerle, M.D., Ph.D. On May 30, 2026, he notified the company that he would step down from the board and its committees, effective May 31, 2026. The company states that his departure is not due to any disagreement regarding operations, policies, or practices.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Board resignation notification date May 30, 2026 Date Hans-Juergen Woerle informed the company
Board resignation effective date May 31, 2026 Effective date of Woerle’s departure from board and committees
Trading symbol MCRB Common stock listed on Nasdaq Global Select Market
Company phone number (617) 945-9626 Registrant’s telephone number
board of directors financial
"resigned from his position as a member of the board of directors of Seres Therapeutics, Inc."
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
Nasdaq Global Select Market financial
"The Nasdaq Stock Market LLC (Nasdaq Global Select Market)"
A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
principal executive offices financial
"Address of principal executive offices"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false 0001609809 0001609809 2026-05-30 2026-05-30
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 30, 2026

 

 

SERES THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-37465   27-4326290

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

101 Cambridgepark Drive

Cambridge, MA

   02140
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 945-9626

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common stock, par value $0.001 per share   MCRB  

The Nasdaq Stock Market LLC

(Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.

On May 30, 2026, Hans-Juergen Woerle, M.D., Ph.D. resigned from his position as a member of the board of directors of Seres Therapeutics, Inc. (the “Company”) and on the committees on which he serves, effective May 31, 2026. Dr. Woerle’s departure is not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    SERES THERAPEUTICS, INC.
Date: June 1, 2026     By:  

/s/ Thomas J. DesRosier

    Name:   Thomas J. DesRosier
    Title:   Chief Legal Officer and Executive Vice President

Source: View Original Filing on SEC EDGAR

FAQ

What board change did Seres Therapeutics (MCRB) disclose in this 8-K?

Seres Therapeutics disclosed that Hans-Juergen Woerle, M.D., Ph.D. resigned from its board of directors and the committees on which he served, effective May 31, 2026. The company states his resignation is not due to any disagreement with its operations, policies, or practices.

When is Hans-Juergen Woerle’s resignation from Seres Therapeutics’ board effective?

Hans-Juergen Woerle’s resignation is effective May 31, 2026. He informed Seres Therapeutics of his decision on May 30, 2026, and the 8-K notes that he is also stepping down from the board committees on which he served.

Did Seres Therapeutics report any disagreement linked to Woerle’s resignation?

Seres Therapeutics stated that Hans-Juergen Woerle’s resignation is not due to any disagreement with the company. The filing specifies there is no disagreement regarding the company’s operations, policies, or practices related to his departure from the board.

What role did Hans-Juergen Woerle hold at Seres Therapeutics before resigning?

Hans-Juergen Woerle served as a member of the board of directors of Seres Therapeutics, Inc. The filing also notes that he sat on certain board committees, from which he will resign effective May 31, 2026, along with his board role.

Who signed the Seres Therapeutics 8-K announcing the board resignation?

The 8-K was signed on behalf of Seres Therapeutics by Thomas J. DesRosier. He is identified in the filing as Chief Legal Officer and Executive Vice President, and he signed the report dated June 1, 2026, for the company.

On which exchange is Seres Therapeutics (MCRB) listed according to the filing?

Seres Therapeutics’ common stock, trading under the symbol MCRB, is listed on The Nasdaq Stock Market LLC. The filing specifies the Nasdaq Global Select Market as the exchange for the company’s common stock with a par value of $0.001 per share.

Filing Exhibits & Attachments

3 documents

Other Documents